Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.69 |
| ▸ | NPC1 | O15118 | 8/20 | 0.67 |
| ▸ | RAB9A | P51151 | 8/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.67 |
| ▸ | HTT | P42858 | 1/20 | 0.67 |
| ▸ | LDHA | P00338 | 2/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24104137 | 0.81 | KMT2A (0.64) | MAPTNPC1RAB9ASMN1; SMN2KMT2A | |
| SCHEMBL30387733 | 0.81 | NPC1 (1.00) | MAPTNPC1RAB9ASMN1; SMN2HTT | |
| SCHEMBL14079746 | 0.81 | LDHA (0.68) | MAPTNPC1RAB9ASMN1; SMN2HTT | |
| SCHEMBL4664159 | 0.80 | LDHA (0.80) | MAPTNPC1RAB9ASMN1; SMN2HTT | |
| SCHEMBL14079745 | 0.80 | LDHA (0.67) | MAPTNPC1RAB9ASMN1; SMN2HTT | |
| SCHEMBL14079744 | 0.80 | LDHA (0.67) | MAPTNPC1RAB9ASMN1; SMN2HTT | |
| SCHEMBL3923955 | 0.78 | LDHA (1.00) | MAPTNPC1RAB9ASMN1; SMN2HTT | |
| SCHEMBL15195866 | 0.77 | LDHA (0.76) | MAPTNPC1RAB9ASMN1; SMN2HTT | |
| SCHEMBL15880590 | 0.77 | MAPT (0.51) | MAPTNPC1RAB9AKMT2AMEN1 | |
| SCHEMBL30300523 | 0.76 | NPC1 (0.73) | MAPTNPC1RAB9ASMN1; SMN2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8877769-B2 | Heteroaryl-substituted urea modulators of fatty acid amide hydrolase | JANSEEN PHARMACEUTICA NV (BG) | 2014-11-04 | — | — | US | disclosed |
| US-8877769-B2 | Heteroaryl-substituted urea modulators of fatty acid amide hydrolase | JANSEEN PHARMACEUTICA NV (BG) | 2014-11-04 | — | — | US | disclosed |
| US-8877769-B2 | Heteroaryl-substituted urea modulators of fatty acid amide hydrolase | JANSEEN PHARMACEUTICA NV (BG) | 2014-11-04 | — | — | US | disclosed |
| US-20130245022-A1 | HETEROARYL-SUBSTITUTED UREA MODULATORS OF FATTY ACID AMIDE HYDROLASE | JANSSEN PHARMACEUTICA NV (US) | 2013-09-19 | — | — | US | disclosed |
| US-20130245022-A1 | HETEROARYL-SUBSTITUTED UREA MODULATORS OF FATTY ACID AMIDE HYDROLASE | JANSSEN PHARMACEUTICA NV (US) | 2013-09-19 | — | — | US | disclosed |
| US-8461159-B2 | Heteroaryl-substituted urea modulators of fatty acid amide hydrolase | Jannsen Pharmaceutica BV (BE) | 2013-06-11 | — | — | US | disclosed |
| US-8461159-B2 | Heteroaryl-substituted urea modulators of fatty acid amide hydrolase | Jannsen Pharmaceutica BV (BE) | 2013-06-11 | — | — | US | disclosed |
| US-8461159-B2 | Heteroaryl-substituted urea modulators of fatty acid amide hydrolase | Jannsen Pharmaceutica BV (BE) | 2013-06-11 | — | — | US | disclosed |
| US-20120083476-A1 | HETEROARYL-SUBSTITUTED SPIROCYCLIC DIAMINE UREA MODULATORS OF FATTY ACID AMIDE HYDROLASE | JANSSEN PHARMACEUTICA NV (BE) | 2012-04-05 | — | — | US | disclosed |
| US-20120083476-A1 | HETEROARYL-SUBSTITUTED SPIROCYCLIC DIAMINE UREA MODULATORS OF FATTY ACID AMIDE HYDROLASE | JANSSEN PHARMACEUTICA NV (BE) | 2012-04-05 | — | — | US | disclosed |
| US-20120083476-A1 | HETEROARYL-SUBSTITUTED SPIROCYCLIC DIAMINE UREA MODULATORS OF FATTY ACID AMIDE HYDROLASE | JANSSEN PHARMACEUTICA NV (BE) | 2012-04-05 | — | — | US | disclosed |
| US-20110237596-A1 | HETEROARYL-SUBSTITUTED UREA MODULATORS OF FATTY ACID AMIDE HYDROLASE | JANSSEN PHARMACEUTICA NV (BE) | 2011-09-29 | — | — | US | disclosed |
| US-20110237596-A1 | HETEROARYL-SUBSTITUTED UREA MODULATORS OF FATTY ACID AMIDE HYDROLASE | JANSSEN PHARMACEUTICA NV (BE) | 2011-09-29 | — | — | US | disclosed |
| US-20110237596-A1 | HETEROARYL-SUBSTITUTED UREA MODULATORS OF FATTY ACID AMIDE HYDROLASE | JANSSEN PHARMACEUTICA NV (BE) | 2011-09-29 | — | — | US | disclosed |
| WO-2010141817-A1 | HETEROARYL-SUBSTITUTED SPIROCYCLIC DIAMINE UREA MODULATORS OF FATTY ACID AMIDE HYDROLASE | JANSSEN PHARMACEUTICA NV (BE) | 2010-12-09 | — | — | WO | disclosed |
| WO-2010141817-A1 | HETEROARYL-SUBSTITUTED SPIROCYCLIC DIAMINE UREA MODULATORS OF FATTY ACID AMIDE HYDROLASE | JANSSEN PHARMACEUTICA NV (BE) | 2010-12-09 | — | — | WO | disclosed |
| WO-2010068453-A1 | HETEROARYL-SUBSTITUTED UREA MODULATORS OF FATTY ACID AMIDE HYDROLASE | JANSSEN PHARMACEUTICA NV (BE) | 2010-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130245022-A1 | HETEROARYL-SUBSTITUTED UREA MODULATORS OF FATTY ACID AMIDE HYDROLASE | FAAH, FAAH2, GPR119 | MAPT 1808/4885NPC1 1573/4885RAB9A 1675/4885 |
| US-20120083476-A1 | HETEROARYL-SUBSTITUTED SPIROCYCLIC DIAMINE UREA MODULATORS OF FATTY ACID AMIDE HYDROLASE | FAAH, FAAH2, DBH | MAPT 1489/4885NPC1 1281/4885RAB9A 1530/4885 |
| US-20110237596-A1 | HETEROARYL-SUBSTITUTED UREA MODULATORS OF FATTY ACID AMIDE HYDROLASE | FAAH, FAAH2, GPR119 | MAPT 1808/4885NPC1 1573/4885RAB9A 1675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.